Neurocognitive Risk With PCSK9 Inhibitors

被引：3
|
作者：
Khan, Abdur Rahman [1 ]
Riaz, Haris [1 ]
Farid, Talha [1 ]
Bolli, Roberto [1 ]
机构：
[1] Univ Louisville, Dept Med, Div Cardiovasc Med, 200 Abraham Flexner Way, Louisville, KY 40202 USA
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2017年 / 69卷 / 19期
基金：
美国国家卫生研究院;
关键词：
CARDIOVASCULAR EVENTS; REDUCING LIPIDS; SAFETY; ALIROCUMAB; EFFICACY;
D O I：
10.1016/j.jacc.2017.02.063
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2468 / 2469
页数：3
相关论文
共 50 条
  • [41] PCSK9 Inhibitors Economics and Policy
    Hlatky, Mark A.
    Kazi, Dhruv S.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 70 (21) : 2677 - 2687
  • [42] PCSK9 inhibitors for treating hypercholesterolemia
    Pasta, Andrea
    Cremonini, Anna Laura
    Pisciotta, Livia
    Buscaglia, Angelo
    Porto, Italo
    Barra, Fabio
    Ferrero, Simone
    Brunelli, Claudio
    Rosa, Gian Marco
    EXPERT OPINION ON PHARMACOTHERAPY, 2020, 21 (03) : 353 - 363
  • [43] PCSK9 inhibitors and cardiovascular outcomes
    Steffens, Daniel
    Bramlage, Peter
    Scheeff, Celine
    Kasner, Mario
    Hassanein, Adel
    Friebel, Julian
    Rauch-Kroehnert, Ursula
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2020, 20 (01) : 35 - 47
  • [44] PCSK9 inhibitors - clinical applications
    Schmidli, Robert
    AUSTRALIAN PRESCRIBER, 2016, 39 (05) : 168 - 170
  • [45] Statins and PCSK9 inhibitors: A new lipid-lowering therapy
    Gallego-Colon, Enrique
    Daum, Aner
    Yosefy, Chaim
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2020, 878
  • [46] PCSK9 inhibitors: current status and emerging frontiers in lipid control
    Agnello, Federica
    Mauro, Maria Sara
    Rochira, Carla
    Landolina, Davide
    Finocchiaro, Simone
    Greco, Antonio
    Ammirabile, Nicola
    Raffo, Carmelo
    Mazzone, Placido Maria
    Spagnolo, Marco
    Occhipinti, Giovanni
    Imbesi, Antonino
    Giacoppo, Daniele
    Capodanno, Davide
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2024, 22 (1-3) : 41 - 58
  • [47] Experience with PCSK9 inhibitors from a Nephrology unit
    Quesada, Veronica Escudero
    Perez, Jonay Pantoja
    Alonso, Cristina Castro
    Capera, July Vanessa Osma
    Anton, Alejandro Valero
    Calabuig, Asuncion Sancho
    NEFROLOGIA, 2024, 44 (01): : 111 - 113
  • [48] PCSK9 inhibitors in familial hypercholesterolemia: What is the evidence?
    Paquette, Martine
    Hegele, Robert A.
    Baass, Alexis
    JOURNAL OF CLINICAL LIPIDOLOGY, 2018, 12 (05) : 1106 - 1108
  • [49] PCSK9 Inhibitors for Homozygous Familial Hypercholesterolemia Useful But Seldom Sufficient
    Thompson, Gilbert R.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 76 (02) : 143 - 145
  • [50] PCSK9 Inhibitors in Secondary Prevention-An Opportunity for Personalized Therapy
    Board, Chase
    Kelly, Michael S.
    Shapiro, Michael D.
    Dixon, Dave L.
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2020, 75 (05) : 410 - 420
12345